X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
o,p'ddd (21) 21
humans (17) 17
index medicus (15) 15
female (13) 13
male (13) 13
endocrinology & metabolism (12) 12
middle aged (12) 12
adult (11) 11
adrenal cortex neoplasms - drug therapy (10) 10
mitotane - therapeutic use (10) 10
mitotane (9) 9
therapy (9) 9
antineoplastic agents, hormonal - therapeutic use (8) 8
mitotane - blood (8) 8
adrenocortical carcinoma (7) 7
aged (7) 7
mitotane - adverse effects (7) 7
o,p'-ddd (7) 7
adrenal cortex neoplasms - blood (6) 6
mitotane - pharmacokinetics (6) 6
retrospective studies (6) 6
adrenal-cortical carcinoma (5) 5
adrenocortical carcinoma - drug therapy (5) 5
antineoplastic agents, hormonal - adverse effects (5) 5
antineoplastic agents, hormonal - blood (5) 5
antineoplastic agents, hormonal - pharmacokinetics (5) 5
mitotane - administration & dosage (5) 5
young adult (5) 5
abridged index medicus (4) 4
adolescent (4) 4
adrenocortical cancer (4) 4
adrenocortical carcinoma - blood (4) 4
antineoplastic agents, hormonal - administration & dosage (4) 4
dose-response relationship, drug (4) 4
drug monitoring (4) 4
experience (4) 4
management (4) 4
neoplasm staging (4) 4
oncology (4) 4
plasma (4) 4
adrenal cortex neoplasms - pathology (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
biochemical research methods (3) 3
cancer (3) 3
chemistry, analytical (3) 3
diagnosis (3) 3
disease (3) 3
follow-up (3) 3
impact (3) 3
metabolites (3) 3
monitored mitotane (3) 3
ortho,para'-ddd (3) 3
pharmacology & pharmacy (3) 3
survival (3) 3
treatment outcome (3) 3
adrenal cancer (2) 2
adrenal cortex - drug effects (2) 2
adrenal cortex - pathology (2) 2
adrenal cortex neoplasms - metabolism (2) 2
adrenal cortex neoplasms - surgery (2) 2
adrenocortical carcinoma - pathology (2) 2
adrenocorticotropic hormone - blood (2) 2
aldrin (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
carcinoma (2) 2
chemotherapy (2) 2
chemotherapy, adjuvant (2) 2
chlorinated hydrocarbon pesticides (2) 2
chromatography, high pressure liquid - methods (2) 2
controversy (2) 2
cushing syndrome - drug therapy (2) 2
cyp3a4 (2) 2
ddd (2) 2
dde (2) 2
ddt (2) 2
dieldrin (2) 2
drug monitoring - methods (2) 2
endocrinology (2) 2
endrin (2) 2
heptachlor (2) 2
hormone (2) 2
hplc-uv (2) 2
hydrocortisone - urine (2) 2
induction (2) 2
lindane (2) 2
liquid chromatography (2) 2
long-term treatment (2) 2
main metabolites (2) 2
medical and health sciences (2) 2
medicin och hälsovetenskap (2) 2
medicine & public health (2) 2
midnight salivary cortisol (2) 2
mitotane - chemistry (2) 2
mitotane - pharmacology (2) 2
o p'ddd (2) 2
o p'ddt (2) 2
p p'ddd (2) 2
p p'ddt (2) 2
pharmacokinetics (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bulletin du Cancer, ISSN 0007-4551, 03/2005, Volume 92, Issue 3, pp. 273 - 279
Journal Article
The Oncologist, ISSN 1083-7159, 03/2018, Volume 23, Issue 3, pp. 389 - 390
In response to the recently published article by Reidy‐Lagunes et al., which deals with clinical response to mitotane treatment in advanced adrenocortical... 
ONCOLOGY | O,P'DDD | Life Sciences | Human health and pathology | Letter to the Editor
Journal Article
European journal of endocrinology / European Federation of Endocrine Societies, ISSN 0804-4643, 2013, Volume 169, Issue 3, pp. 263 - 270
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 12/2013, Volume 98, Issue 12, pp. 4759 - 4767
Context: Mitotane is the only approved drug for treatment of adrenocortical carcinoma. Its pharmacokinetic properties are not fully elucidated and different... 
METABOLITES | THERAPY | PLASMA | PHARMACOLOGY | O,P'-DDD | ENDOCRINOLOGY & METABOLISM | MONITORED MITOTANE | O,P'DDD | CYP3A4 | CANCER | CLINICAL MANAGEMENT | Dichlorodiphenyl Dichloroethylene - blood | Adrenal Cortex Neoplasms - blood | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Gastrointestinal Diseases - physiopathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Adrenal Cortex - pathology | Antineoplastic Agents, Hormonal - pharmacokinetics | Dose-Response Relationship, Drug | Adrenocortical Carcinoma - pathology | Antineoplastic Agents, Hormonal - adverse effects | Adrenocortical Carcinoma - drug therapy | Drug Interactions | Antineoplastic Agents, Hormonal - therapeutic use | Biotransformation | Adult | Female | Adrenal Cortex - drug effects | Mitotane - administration & dosage | Severity of Illness Index | Adrenocortical Carcinoma - secondary | Antineoplastic Agents, Hormonal - administration & dosage | Mitotane - adverse effects | Adrenal Cortex Neoplasms - pathology | Mitotane - therapeutic use | Mitotane - pharmacokinetics | Adrenal Cortex Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neurotoxicity Syndromes - physiopathology | Adrenocortical Carcinoma - blood | Drug Monitoring | Neoplasm Staging | Gastrointestinal Diseases - chemically induced | Phenylacetates - blood
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 08/2015, Volume 100, Issue 8, pp. 2890 - 2898
Context: Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating... 
SURVIVAL | ORTHO,PARA'-DDD | CELLS | MANAGEMENT | NORMOTRIGLYCERIDEMIA | RAT | SERUM LEVEL | ENDOCRINOLOGY & METABOLISM | MONITORED MITOTANE | O,P'DDD | CANCER
Journal Article
Journal Article
Journal Article